Plasma proteomic profiling in patients with atopic dermatitis following the administration of Nemolizumab

ratsuji Hideya0 个研究点目标入组 35 人开始时间: 2023年11月22日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1) Group with AD patients
•Stored plasma samples collected from AD patients with moderate or severe pruritus in the clinical trial (jRCT2080225290) will be used.
•2)Group with healthy volunteers
•Individuals who have never been diagnosed with AD in the past and are not currently diagnosed with AD
•Individuals who can collect blood samples following a set procedure

•Group with healthy volunteers
•Individuals with a history of, or currently suffering from, severe diseases, including severe allergic diseases
•Individuals who have administered medications containing immunomodulatory drugs (immunosuppressants, steroids or biological agents) within one month for topical drugs and within six months for oral or injectable drugs, counting from the blood collection date
•Individuals who are currently undergoing treatment for a disease or who have received treatment within the past week
•Individuals with a constitution such as atopic predisposition or allergy-prone
•Individuals who have been advised to seek treatment or more serious intervention based on their most recent regular health check-up
•Individuals who fall under the conditions listed in the 'Cases where you should refrain from donating' section on the Japanese Red Cross Society website
•Individuals with a history of, or currently suffering from, drug or alcohol dependency
•Individuals who are pregnant or currently breastfeeding
•Individuals considered inappropriate for the study by the principal investigator of the clinical research

发起方

ratsuji Hideya